Pathological complete response to neoadjuvant alectinib in unresectable anaplastic lymphoma kinase positive non-small cell lung cancer: A case report

Table 1 Summary of all cases of anaplastic lymphoma kinase positive patient receiving neoadjuvant alectinib therapy

	Zhang et al[13]	Yue et al[14]	Leonetti et al[15]	Hu et al[16]	Present case
Age/gender	46/male	51/male	62/male	58/female	41/male
Symptoms	Cough and hemoptysis	None	NA	Hemoptysis	None
Smoking status	Nonsmoker	Nonsmoker	Former smoker	Nonsmoker	Nonsmoker
Location	Left lower lobe	Right upper lobe	Left upper lobe	Right lower lobe	Left upper lobe
Tumor size (cm)	6.6	3.1	NA	4.2	3.9
Baseline cTNM	cIIIB (cT3N2M0)	cIIIA (cT2N2M0)	cIIIA (cT2aN2M0)	cIIIA (cT2bN2M0)	cIIIB (cT2aN3M0)
Operable/inoperable	Inoperable	Operable	Operable	Operable	Inoperable
Cycles	2	1	2	2	14
Radiologic response	PR	PR	PR	PR	PR
Pathologic response	Non-MPR	Non-MPR	MPR	pCR	pCR
Downstaging after alectinib therapy	Yes	No	Yes	Yes	Yes
Adverse effects	Grade 1 constipation	None	None	Grade 1 constipation; Grade 1 erythema	Grade 1 abnormal liver function
Follow-up	NA	Free of disease for 6 mo	NA	Free of disease for 8 mo	Free of disease for 26 mo

NA: Not available; PR: Partial response; MPR: Major pathologic response; pCR: Pathological complete response.